curseofthewerewolfmegaways| Heyu-B (02256.HK): Carry out a clinical study of ABSK043 combined with fumetinib mesylate tablets in the treatment of advanced non-small cell lung cancer

Gelonghui May 9 丨 Heyu-B (02256curseofthewerewolfmegaways.HK) issued an announcement, which is under researchcurseofthewerewolfmegawaysABSK043, an oral small molecule PD-L1 inhibitor, will soon carry out clinical research on the combination treatment of advanced non-small cell lung cancer with vormetinib mesylate tablets (trade name: Ifosa,"vormetinib") independently developed by Ellis (688578.SH).

Tags:

Prev: pokerjourney| Invesco Great Wall Prosperity and Aggressive Hybrid A(013812): Net value of 0.6881 yuan, yield of 3.32% in the past month
Next: vola777win| In the first four months, 40 mixed bases rose by more than 20% and Nuoan's positive return rose by 24%